Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.26.

ANTH has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 8th. Jefferies Group LLC reissued a “hold” rating and set a $2.25 target price on shares of Anthera Pharmaceuticals in a research report on Monday, May 15th. Finally, ValuEngine downgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/11/anthera-pharmaceuticals-inc-anth-receives-average-rating-of-hold-from-analysts.html.

Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 2.00% during midday trading on Tuesday, reaching $1.53. The company’s stock had a trading volume of 188,198 shares. Anthera Pharmaceuticals has a 12 month low of $1.47 and a 12 month high of $32.00. The stock’s 50-day moving average price is $1.76 and its 200-day moving average price is $1.06. The firm’s market capitalization is $15.42 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.47) by $0.56. Analysts predict that Anthera Pharmaceuticals will post ($5.06) EPS for the current year.

Several large investors have recently modified their holdings of ANTH. Sabby Management LLC increased its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares in the last quarter. UBS Group AG increased its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.